Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 11:08 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2449–2472 of 3,500 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Protein Control Clear all

Conditions: Psoriatic Arthritis
Interventions: Alefacept, Methotrexate, Placebo; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 185 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 5
States / cities: Birmingham, Alabama • Wheaton, Maryland • Lake Success, New York + 2 more

Conditions: Oral Glucose Tolerance Test, High Fat Tolerance Test
Interventions: non-fat milk, carbohydrate control beverage, caloric control beverage; Dietary Supplement
Lead sponsor: University of Texas at Austin; Other
Eligibility: 20 Years to 40 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Rheumatoid Arthritis
Interventions: Certolizumab pegol (CZP), Placebo; Drug · Other
Lead sponsor: UCB Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 1,648 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 101
States / cities: Birmingham, Alabama • Montgomery, Alabama • Phoenix, Arizona + 98 more

Conditions: Diabetes Mellitus, Type 2, NASH - Nonalcoholic Steatohepatitis
Interventions: ORMD-0801 (Insulin) capsule 8 mg BD, Placebo; Drug · Other
Lead sponsor: Oramed, Ltd.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Tustin, California

Conditions: Pain, Breast Cancer, Lung Cancer
Interventions: Gabapentin, Lorazepam (active control), Placebo (inactive); Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 422 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 1
States / cities: Stanford, California

Conditions: Non-Small Cell Lung Cancer, Anemia, Cancer, Lung Cancer
Interventions: Darbepoetin alfa, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 2,549 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2017
U.S. locations: 277
States / cities: Anniston, Alabama • Birmingham, Alabama • Anchorage, Alaska + 243 more

Conditions: Musculoskeletal Abnormalities, Obesity, Sarcopenic Obesity, Osteoporosis, Drug Effect
Interventions: Tirzepatide, Lifestyle toolkit; Drug · Behavioral
Lead sponsor: Pennington Biomedical Research Center; Other
Eligibility: 18 Years to 50 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Baton Rouge, Louisiana • Scarborough, Maine

Conditions: Immunity
Interventions: An arginine rich nutritional supplement; Dietary Supplement
Lead sponsor: Martin Angst; Other
Eligibility: 18 Years to 65 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Stanford, California

Conditions: HIV Infections
Interventions: Recombinant human interleukin-7; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 5
States / cities: Sacramento, California • Miami, Florida • Chicago, Illinois + 1 more

Conditions: Trauma, Hemorrhage
Interventions: Calcium Gluconate, Vasopressin, saline placebo; Drug
Lead sponsor: Jason Sperry; Other
Eligibility: 18 Years to 90 Years
Enrollment: 1,050 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 18
States / cities: Chandler, Arizona • Tucson, Arizona • Little Rock, Arkansas + 13 more

Conditions: Cervical Cancer
Interventions: Pembrolizumab, Paclitaxel, Cisplatin, Carboplatin, Bevacizumab, Placebo to pembrolizumab; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 617 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 20
States / cities: Anchorage, Alaska • Phoenix, Arizona • Orange, California + 15 more

Conditions: Stress, Ageing, Wellbeing
Interventions: Meditation Retreat, Active Comparator Relaxation Group; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 30 Years to 60 Years · Female only
Enrollment: 96 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Carlsbad, California

Conditions: High Risk Newly Diagnosed Multiple Myeloma
Interventions: Bispecific Monoclonal Antibody and Triplet Therapy, Monoclonal Antibody with Stem Cell Transplant; Drug
Lead sponsor: Multiple Myeloma Research Consortium; Network
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2035
U.S. locations: 12
States / cities: Duarte, California • Atlanta, Georgia • Chicago, Illinois + 8 more

Conditions: Type 1 Diabetes Mellitus
Interventions: SAR438544, placebo, r-glucagon; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Heart Diseases, Cardiovascular Diseases
Interventions: Dr. Dean Ornish Program for Reversing Heart Disease; Behavioral
Lead sponsor: Windber Research Institute; Other
Eligibility: 21 Years and older
Enrollment: 422 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2009
U.S. locations: 1
States / cities: Windber, Pennsylvania

Conditions: Hypoalbuminemia, Protein-energy Malnutrition, Inflammation, Oxidative Stress, Chronic Kidney Disease (CKD) Hemodialysis
Interventions: pentoxiphylline, Nepro, anti-inflammatory module (similar to Oxepa), Placebo pill imitating pentoxiphylline, Placebo to imitate Nepro, Placebo to imitate anti-inflammatory module (similar to Oxepa); Drug · Dietary Supplement
Lead sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center; Other
Eligibility: 18 Years to 85 Years
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 2
States / cities: Irvine, California • Torrance, California

Conditions: Central Venous Catheter Thrombosis, Central Venous Catheter Associated Bloodstream Infection
Interventions: alteplase (recombinant t-PA), Heparin; Biological · Drug
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: Up to 18 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes
Interventions: autologous expanded mesenchymal stem cells OTI-010, busulfan, cyclophosphamide, cyclosporine, methotrexate, peripheral blood stem cell transplantation, radiation therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: Mesoblast International Sàrl; Industry
Eligibility: 18 Years to 55 Years
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Glioblastoma Multiforme
Interventions: Selinexor, Temozolomide (TMZ), Lomustine (CCNU), Standard Fractionated Radiation therapy (RT), Bevacizumab, TTField, Carmustine; Drug · Radiation · Device
Lead sponsor: Karyopharm Therapeutics Inc; Industry
Eligibility: 18 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 17
States / cities: Birmingham, Alabama • Los Angeles, California • San Francisco, California + 12 more

Conditions: Eosinophilic Esophagitis, Milk Allergy
Interventions: Viaskin Milk 500 mcg, Viaskin Placebo; Drug
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 4 Years to 17 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Uterine Fibroids
Interventions: Proellex 25 mg, Proellex 50 mg, Lupron Depot; Drug
Lead sponsor: Repros Therapeutics Inc.; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 3
States / cities: Sarasota, Florida • Houston, Texas

Conditions: Sarcoma
Interventions: filgrastim, doxorubicin hydrochloride, ifosfamide, mesna, vincristine sulfate, conventional surgery, brachytherapy, low-LET cobalt-60 gamma ray therapy, low-LET electron therapy, low-LET photon therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 21 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2006
U.S. locations: 7
States / cities: Wichita, Kansas • New Orleans, Louisiana • Memphis, Tennessee + 4 more

Conditions: Diabetes During Pregnancy
Interventions: High-Protein Beverage (Genius Gourmet Sparkling Protein Water), Standard Clear Liquid Diet, Continuous Glucose Monitoring (Abbott Freestyle Libre); Dietary Supplement · Other · Device
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Vocal Fold Palsy, Vocal Cord Paralysis, Vocal Cord Atrophy
Interventions: Silk Voice; Device
Lead sponsor: Sofregen Medical, Inc.; Industry
Eligibility: 22 Years to 65 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Chicago, Illinois

Search by objective public record fields.

A Placebo-controlled Study With an Extension Examining the Safety and Efficacy of Alefacept in Psoriatic Arthritis

Effects of Fluid Milk in Attenuating Hyperglycemia and Hypertriglyceridemia After Meal

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis

A Study to Assess the Safety and Efficacy of Oral Insulin in T2DM Patients With Nonalcoholic Steatohepatitis (NASH)

Stanford Accelerated Recovery Trial (START)

Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy

GLP-1R Actions on Muscle and the Skeleton

Immune-modulation Effects of an Arginine Rich Nutritional Supplement in Surgical Patients

Safety of Interleukin-7 in HIV Infected People Currently Taking Anti-HIV Drugs

CAlcium and VAsopressin Following Injury Early Resuscitation (CAVALIER) Trial

Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-826)

The Relaxation vs. Retreat Study

Horizon Two: HR NDMM (MMRC-100)

A Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Doses of SAR438544 in Comparison to Placebo and Glucagon in Healthy Subjects and Type 1 Diabetes Mellitus Patients

Global Profiling of Gene and Protein Expression Associated With Coronary Heart Disease Reversal

Anit-Inflammatory and Anti-Oxidative Nutrition in Dialysis Patients

t-PA Prophylaxis to Prevent Catheter-associated Thrombosis and Infection

OTI-010 for Graft-Versus-Host Disease Prophylaxis in Treating Patients Who Are Undergoing Donor Peripheral Stem Cell Transplantation for Hematologic Malignancies

A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma

Milk Patch for Eosinophilic Esophagitis

Pharmacokinetics, Safety and Efficacy Study of Proellex in Pre-menopausal Women With Symptomatic Uterine Fibroids

Combination Chemotherapy, Surgery, and Radiation Therapy in Treating Children With Advanced Soft Tissue Sarcoma

Fueling Labor: Protein Supplementation for Intrapartum Glucose Control

A Histological Study Evaluating Silk Voice and Crosslinked Hyaluronic Acid